Literature DB >> 27904430

Natalizumab-Related Progressive Multifocal Leukoencephalopathy-Immune Reconstitution Inflammatory Syndrome: A Case Report Highlighting Clinical and MRI Features.

Bela Purohit1, Eranga Ganewatte2, Spyros S Kollias2.   

Abstract

Multiple sclerosis (MS) patients treated with natalizumab often face the uncommon but severe complication of developing progressive multifocal leukoencephalopathy (PML). PML may be further complicated by immune reconstitution inflammatory syndrome (IRIS) after the removal of the drug. Since both PML and IRIS are associated with high morbidity and mortality rates, early clinical and radiological diagnosis of these complications is of paramount importance. Here, we report a case of an adult male patient who was diagnosed with PML after receiving natalizumab therapy for 6 years for the treatment of MS. Upon cessation of natalizumab, he presented with a paradoxical worsening of clinical and radiological findings consistent with an inflammatory brain injury due to IRIS. He was treated with high dose corticosteroid therapy followed by a gradual improvement in clinical and imaging findings. This article illustrates the magnetic resonance imaging (MRI) features of natalizumab-associated PML-IRIS, along with a brief overview of its clinical features, complications and management strategies.

Entities:  

Keywords:  immune reconstitution inflammatory syndrome; magnetic resonance imaging; multiple sclerosis; natalizumab; progressive multifocal leukoencephalopathy

Year:  2016        PMID: 27904430      PMCID: PMC5101973          DOI: 10.21315/mjms2016.23.5.12

Source DB:  PubMed          Journal:  Malays J Med Sci        ISSN: 1394-195X


  12 in total

1.  Risk of natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Gary Bloomgren; Sandra Richman; Christophe Hotermans; Meena Subramanyam; Susan Goelz; Amy Natarajan; Sophia Lee; Tatiana Plavina; James V Scanlon; Alfred Sandrock; Carmen Bozic
Journal:  N Engl J Med       Date:  2012-05-17       Impact factor: 91.245

Review 2.  Natalizumab-associated progressive multifocal leukoencephalopathy in patients with multiple sclerosis: lessons from 28 cases.

Authors:  David B Clifford; Andrea De Luca; Andrea DeLuca; David M Simpson; Gabriele Arendt; Gavin Giovannoni; Avindra Nath
Journal:  Lancet Neurol       Date:  2010-04       Impact factor: 44.182

Review 3.  Update on PML and PML-IRIS occurring in multiple sclerosis patients treated with natalizumab.

Authors:  B K Kleinschmidt-DeMasters; Augusto Miravalle; Jeffrey Schowinsky; John Corboy; Timothy Vollmer
Journal:  J Neuropathol Exp Neurol       Date:  2012-07       Impact factor: 3.685

4.  Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy.

Authors:  Augusto Miravalle; Rikke Jensen; R Philip Kinkel
Journal:  Arch Neurol       Date:  2010-10-11

5.  Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS.

Authors:  S Gheuens; D R Smith; X Wang; D C Alsop; R E Lenkinski; I J Koralnik
Journal:  Neurology       Date:  2012-04-18       Impact factor: 9.910

Review 6.  Natalizumab treatment for multiple sclerosis: updated recommendations for patient selection and monitoring.

Authors:  Ludwig Kappos; David Bates; Gilles Edan; Mefkûre Eraksoy; Antonio Garcia-Merino; Nikolaos Grigoriadis; Hans-Peter Hartung; Eva Havrdová; Jan Hillert; Reinhard Hohlfeld; Marcelo Kremenchutzky; Olivier Lyon-Caen; Ariel Miller; Carlo Pozzilli; Mads Ravnborg; Takahiko Saida; Christian Sindic; Karl Vass; David B Clifford; Stephen Hauser; Eugene O Major; Paul W O'Connor; Howard L Weiner; Michel Clanet; Ralf Gold; Hans H Hirsch; Ernst-Wilhelm Radü; Per Soelberg Sørensen; John King
Journal:  Lancet Neurol       Date:  2011-08       Impact factor: 44.182

7.  Magnetic resonance imaging pattern in natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Tarek A Yousry; Daniel Pelletier; Diego Cadavid; Achim Gass; Nancy D Richert; Ernst-Wilhelm Radue; Massimo Filippi
Journal:  Ann Neurol       Date:  2012-11       Impact factor: 10.422

8.  Pathology of immune reconstitution inflammatory syndrome in multiple sclerosis with natalizumab-associated progressive multifocal leukoencephalopathy.

Authors:  Imke Metz; Ernst-Wilhelm Radue; Agustin Oterino; Tania Kümpfel; Heinz Wiendl; Sven Schippling; Jens Kuhle; Mohammad Ali Sahraian; Francoise Gray; Veronika Jakl; Darius Häusler; Wolfgang Brück
Journal:  Acta Neuropathol       Date:  2011-11-06       Impact factor: 17.088

Review 9.  Efficacy and side effects of natalizumab therapy in patients with multiple sclerosis.

Authors:  Robert Hoepner; Simon Faissner; Anke Salmen; Ralf Gold; Andrew Chan
Journal:  J Cent Nerv Syst Dis       Date:  2014-04-28

Review 10.  Management of patients with the immune reconstitution inflammatory syndrome.

Authors:  Suzaan Marais; Robert J Wilkinson; Dominique J Pepper; Graeme Meintjes
Journal:  Curr HIV/AIDS Rep       Date:  2009-08       Impact factor: 5.495

View more
  1 in total

Review 1.  Neurological safety of fingolimod: An updated review.

Authors:  Fumihito Yoshii; Yusuke Moriya; Tomohide Ohnuki; Masafuchi Ryo; Wakoh Takahashi
Journal:  Clin Exp Neuroimmunol       Date:  2017-06-18
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.